50-198-7927
GPR55 Rabbit anti-Human, Polyclonal, Bioss
Manufacturer: Bioss
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-198-7927-Each-of-1 | In Stock | ₹ 38,381.25 |
50-198-7927 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 38,381.25
GST (18%): ₹ 6,908.625
Total Price: ₹ 45,289.875
Antigen
GPR55
Classification
Polyclonal
Conjugate
Unconjugated
Gene
GPR55
Gene Alias
G protein-coupled receptor 55; GPCR55; GPR55; G-protein coupled receptor 55; LPIR1
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
9290
Content And Storage
-20°C
Form
Liquid
Applications
Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot
Concentration
1 μg/mL
Formulation
PBS with 1% BSA, 50% glycerol and 0.09% sodium azide; pH
Gene Accession No.
Q9Y2T6
Gene Symbols
GPR55
Immunogen
KLH conjugated synthetic peptide derived from human GPR55.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- GPR55 has been reported to be expressed in the brain, where mRNA transcripts were detected in the caudate nucleus and putamen, but not in five other brain regions (Sawzdargo et al., 1999)
- ESTs have been isolated from liver/spleen libraries
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This 'turn-off' activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.